发生率与危险因素最初的报告提示,采用 MTX 治疗的患者,发生肺毒性反应达33%以上.但这些报告尚未除外感染.最近的回顾性研究发现,在92例采用 MTX 治疗的患者中,7例显示肺功能不全表现而不能归因于感染或原发病.因此,7.6%这个数值可能是肺毒性发生率的最正确估计.所有已知的诱因包括年龄、总剂量、疗程和原发病等均影响肺毒性的发生,但给药的频率可能最重要。文献提及,使用 MT Rates and risk factors Initial reports suggest that patients who receive MTX have developed more than 33% of lung toxicity, but these reports have not been excluded, and a recent retrospective study found that among the 92 MTX-treated patients, 7 Cases showing pulmonary insufficiency but not attributable to infection or primary disease Therefore, a value of 7.6% may be the most accurate estimate of the incidence of pulmonary toxicity All known triggers include age, total dose, duration of treatment, and primary disease And so affect the occurrence of pulmonary toxicity, but the frequency of administration may be the most important. The literature mentions the use of MT